• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

FDA decision nears on Aimmune's contested peanut allergy drug

cafead

Administrator
Staff member
  • cafead   Jan 24, 2020 at 12:22: PM
via If the Food and Drug Administration follows the advice of its outside advisers, the agency will within days grant the first-ever approval to a drug designed to make peanut allergy sufferers less likely to have a dangerous reaction.

Called Palforzia, the drug was developed by the California-based biotech Aimmune. It's in close competition with a French company called DBV Technologies, which should see the FDA decide on its patch-based peanut allergy treatment by August.

article source
 

<